Harrow, Inc. Operating Leases, Income Statement, Depreciation Expense on Property Subject to or Held-for-lease
Harrow, Inc. (HROW) reported Operating Leases, Income Statement, Depreciation Expense on Property Subject to or Held-for-lease of $2.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease · last filed 2021-11-09
- Harrow, Inc. operating leases, income statement, depreciation expense on property subject to or held-for-lease for the quarter ending 2021-09-30 was $2.00K, a 0.00% change year-over-year.
- Harrow, Inc. operating leases, income statement, depreciation expense on property subject to or held-for-lease for the quarter ending 2021-06-30 was $2.00K, a 0.00% change year-over-year.
- Harrow, Inc. operating leases, income statement, depreciation expense on property subject to or held-for-lease for the quarter ending 2021-03-31 was $2.00K, a 0.00% change year-over-year.
- Harrow, Inc. operating leases, income statement, depreciation expense on property subject to or held-for-lease for the quarter ending 2020-09-30 was $2.00K, a 0.00% change year-over-year.
- Harrow, Inc. operating leases, income statement, depreciation expense on property subject to or held-for-lease for fiscal 2019 was $150.00K.
| Period end | Operating Leases, Income Statement, Depreciation Expense on Property Subject to or Held-for-lease 3 month | Operating Leases, Income Statement, Depreciation Expense on Property Subject to or Held-for-lease 6 month | Operating Leases, Income Statement, Depreciation Expense on Property Subject to or Held-for-lease 9 month | Operating Leases, Income Statement, Depreciation Expense on Property Subject to or Held-for-lease 12 month |
|---|---|---|---|---|
| 2021-09-30 | $2.00K 10-Q · filed 2021-11-09 | $4.00K derived: sum of 2 quarters · filed 2021-11-09 | $6.00K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $2.00K 10-Q · filed 2021-08-10 | $4.00K 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | $2.00K 10-Q · filed 2021-05-11 | |||
| 2020-09-30 | $2.00K 10-Q · filed 2020-11-09 | $4.00K derived: sum of 2 quarters · filed 2020-11-09 | $6.00K 10-Q · filed 2020-11-09 | $8.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2020-06-30 | $2.00K 10-Q · filed 2020-08-10 | $4.00K 10-Q · filed 2020-08-10 | $6.00K derived: sum of 3 quarters · filed 2020-08-10 | $8.00K derived: sum of 4 quarters · filed 2020-08-10 |
| 2020-03-31 | $2.00K 10-Q · filed 2020-05-11 | $4.00K derived: sum of 2 quarters · filed 2020-05-11 | $6.00K derived: sum of 3 quarters · filed 2020-05-11 | $79.00K derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $4.00K derived: sum of 2 quarters · filed 2020-03-13 | $77.00K derived: sum of 3 quarters · filed 2020-03-13 | $150.00K 10-K · filed 2020-03-13 |
| 2019-09-30 | $2.00K 10-Q · filed 2019-11-13 | $75.00K derived: sum of 2 quarters · filed 2019-11-13 | $148.00K 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $73.00K 10-Q · filed 2019-08-14 | $146.00K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $73.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |